Is There a Mounjaro Pill? Oral Tirzepatide Options Explained

Why there is no Mounjaro pill

Tirzepatide is a 39-amino-acid peptide — a large molecule that gets broken down by digestive enzymes before it can reach your bloodstream. That is the same reason insulin requires injection. Making an oral version would require either protecting the molecule through digestion (which added years and absorption enhancers to Rybelsus's development) or building a fundamentally different molecule.

Lilly chose the second path: instead of a tirzepatide pill, it developed orforglipron, a small-molecule oral GLP-1 agonist that survives digestion with no special absorption technology. It is not tirzepatide — it is a new drug aimed at the same market.

Your actual pill options in 2026

Orforglipron: the closest thing to a Mounjaro pill

Orforglipron, to be sold as Foundayo, is Lilly's oral, non-peptide GLP-1 receptor agonist. Unlike tirzepatide it is a single-agonist (GLP-1 only, no GIP), but Phase 3 results showed around 12% average body weight loss at the highest dose over 72 weeks — meaningful results with no needle and no fasting requirement like Rybelsus has.

Approval is widely expected once the Phase 3 program completes. Read our Foundayo and orforglipron guide for the trial data, pricing projections, and how it compares to Wegovy's pill.

What about compounded tirzepatide drops?

Some compounding pharmacies sell sublingual tirzepatide — drops held under the tongue that absorb through the oral mucosa. This is not a pill: it bypasses digestion entirely. Absorption is less predictable than injection and the clinical data is thin, but it is a real option for needle-averse patients. A true swallowable tirzepatide pill, however, does not exist and is not scientifically viable with current technology.

Frequently asked questions

Does a Mounjaro pill exist?

No. Mounjaro (tirzepatide) is only available as a once-weekly subcutaneous injection. Eli Lilly has not released a pill version. The only oral GLP-1 medications currently on the market are Rybelsus (oral semaglutide) and the new Wegovy pill in the US.

Is Lilly making a weight loss pill?

Yes — but it is a different drug called orforglipron (brand name Foundayo), not a tirzepatide pill. Orforglipron is an oral, non-peptide GLP-1 receptor agonist in Phase 3 trials showing roughly 12% average weight loss. FDA approval is expected after the Phase 3 program completes.

What pill is closest to Mounjaro?

The Wegovy pill (oral semaglutide at higher doses) is the closest approved option, averaging about 15% weight loss in OASIS-4. Rybelsus is approved for diabetes but used off-label for weight loss. Neither is a GIP/GLP-1 dual agonist like tirzepatide.

Can you get compounded tirzepatide as drops or a pill?

Some compounding pharmacies offer sublingual tirzepatide drops, but no oral pill form has proven absorption — tirzepatide is a large peptide that stomach acid destroys. Sublingual absorption is less studied than injection.

What is the cheapest way to get tirzepatide-like results?

Compounded tirzepatide via licensed US telehealth programs runs $199 to $299/month vs $1,000+ retail for Mounjaro. It still requires injection, but it delivers the same molecule at a fraction of the cost.

Bottom line

There is no Mounjaro pill and there will not be one — the molecule cannot survive digestion. If you want pill-form GLP-1 treatment now, the Wegovy pill is the strongest approved option. If you want tirzepatide's ~21% results, injection is the only route — and licensed telehealth programs make it far more affordable than retail Mounjaro.